GLIOSARCOMA

This early-stage study is testing whether adding an experimental drug called S-Gboxin to standard brain cancer treatment helps control aggressive tumors like glioblastoma. It will involve about 10 patients with these difficult-to-treat cancers. Researchers will monitor how patien…

This early study is testing whether daily progesterone injections can help control tumor growth in adults whose aggressive brain cancer (glioblastoma) has returned. Researchers want to find the safest dose and see if the treatment can stabilize the disease. The study involves a v…

This study is testing whether adding an experimental vaccine called SurVaxM to standard chemotherapy (temozolomide) can help control a serious brain cancer called glioblastoma. The vaccine is designed to teach the body's immune system to recognize and attack cancer cells. The tri…

This study is testing whether adding immune-boosting drugs (nivolumab and ipilimumab) to standard chemotherapy can help people with newly diagnosed glioblastoma, a very aggressive brain cancer. Researchers will track 47 adults who have already had surgery and initial treatment, l…

This early-stage trial is testing whether adding an experimental drug called selinexor to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. Researchers want to find the highest dose of selinexor that patients can…

This study is testing if adding a second chemotherapy drug, lomustine, to the current standard treatment helps people with a newly diagnosed, aggressive brain tumor live longer. It is for adults aged 18-70 with a specific tumor type (MGMT methylated glioblastoma) who have not had…

This study is testing whether adding an experimental drug called veliparib to standard chemotherapy (temozolomide) helps patients with newly diagnosed glioblastoma, a fast-growing brain cancer, live longer. About 447 patients whose tumors have a specific genetic feature (MGMT pro…

This study is testing whether a special type of MRI scan can predict how well patients with recurrent glioblastoma (a type of brain cancer) will respond to the drug bevacizumab. Researchers are measuring changes in blood flow within the tumor two weeks after starting treatment to…